Skip to content
Allegro Ophthalmics - From Theory to Therapy
  • About
    • Company
    • Management
    • Board of Directors
    • Scientific Advisors
  • Science
  • Pipeline
    • Pipeline
    • Risuteganib
    • ALG-1007
    • Clinical Trials
  • Therapeutic Areas
    • Dry AMD
    • Dry Eye Disease
  • News
    • Press Releases
    • Allegro in the News
    • Events
Allegro Ophthalmics - From Theory to Therapy

Setting the pace in ocular care
Read More >

Allegro Ophthalmics LLC
31473 Rancho Viejo Road, Suite 207
San Juan Capistrano, CA 92675, USA
Phone: +1 949.940.8130
Email: info@allegroeye.com

RECENT NEWS

Allegro Ophthalmics Licensee AffaMed Therapeutics Receives Phase 3 CTA Approval in China for Risuteganib for the Treatment of Intermediate Dry AMD
September 25, 2023

Allegro Ophthalmics Receives FDA Agreement Under Special Protocol Assessment (SPA) for Phase 2b/3 Clinical Trial of Risuteganib for the Treatment of Intermediate Dry AMD
April 13, 2023

  • About
  • Science
  • Pipeline
  • Therapeutic Areas
  • News
  • Careers
  • Contact Us
© 2025 Allegro Ophthalmics, LLC. All rights reserved. | Privacy Policy | Terms of Use